|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| End Stage Renal Disease | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Inflammation | |||||
| Insulin Resistance | |||||
| Kidney Diseases | |||||
| Kidney Failure, Chronic | |||||
| 3 | More general conditions related to this trial | ||||
| Glucose Metabolism Disorders | |||||
| Hyperinsulinism | |||||
| Kidney Failure | |||||
| Metabolic Diseases | |||||
| Pathologic Processes | |||||
| Renal Insufficiency | |||||
| Renal Insufficiency, Chronic | |||||
| Urologic Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| paricalcitol | |||||
| cinacalcet | |||||
| 5 | Sponsors listed in this trial | ||||
| Vanderbilt University | |||||